Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AbCellera Biologics Inc (ABCL) vs Nutanix Inc (NTNX) Price & Performance

AbCellera Biologics IncTrade
Nutanix IncTrade

Price performance (Past 24H)

Key statistics

AbCellera Biologics Inc vs Nutanix Inc — how do they compare? AbCellera Biologics Inc trades at $10.15 (market cap $2.99B), while Nutanix Inc trades at $64.45 (market cap $17.39B). The key difference: Nutanix Inc is far larger — about 5.8× AbCellera Biologics Inc's market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, Nutanix Inc nearer its low. Which is the better fit depends on your goals.

ABCLNTNX
Market Cap
$2.99B$17.39B
Sector
HealthTechnology
52-Week High
$9.76$81.12
52-Week Low
$2.78$34.41
Enterprise Value
$2.58B$16.90B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AbCellera Biologics Inc

ABCL's stock rose 7.07% to $10.00, buoyed by positive Phase 2 trial results for its menopause drug ABCL635, which demonstrated an 83% reduction in hot flashes (Business Wire, August 10, 2026). Despite negative profitability margins and cash burn, technical indicators show a bullish trend with strong moving average support. The company maintains a solid balance sheet with $625.61 million in cash and low debt, though revenue declined from $485 million in 2022 to $75 million in 2025.

The outlook hinges on clinical success and monetization of ABCL635, with a consensus price target of $15.50 implying 55% upside. Key risks include prolonged cash burn, drug development setbacks, and competitive pressures. Analyst sentiment is overwhelmingly bullish (91.67% buy ratings), but investors must weigh high valuation multiples against unproven commercial traction.

Nutanix Inc

Nutanix (NTNX) trades at $64.32, down 0.22% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $0.47 surpassing the $0.36 expectation. Revenue grew to $2.54B in 2025 with a net income margin of 7.42%, while 2026 projections show improved profitability. Analyst sentiment remains positive with 20 buy ratings and a $57.80 consensus price target.

The outlook for NTNX is supported by strong earnings momentum and institutional interest, though high valuation multiples (P/E 67.71) and supply chain risks noted in recent news pose challenges. The stock's proximity to resistance at $65.00 suggests near-term consolidation may occur before further gains.

Returns comparison

Trailing returns across standard periods

About AbCellera Biologics Inc

AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.

Read more on ABCL

About Nutanix Inc

Nutanix, Inc. is a global leader in cloud software and hyperconverged infrastructure (HCI) solutions. The company's platform converges computing, virtualization, and storage into a single, seamless software-defined solution, enabling private, hybrid, and multi-cloud environments. Nutanix helps organizations simplify data center operations, manage their applications across various cloud platforms, and reduce IT complexity, positioning it as a key enabler of modern hybrid cloud strategies.

Read more on NTNX